Company intelligence / Profile preview
iLeadBMS
Seoul (headquarters), South Koreaileadbms.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Presented preclinical data on IL21120038, a CXCR7 agonist for heart failure treatment, showing reduced infarct area, lower heart damage markers, increased cardiac output, and reduced inflammation and fibrosis in rat models. The compound demonstrated superior efficacy compared to Entresto®[4].
- Therapeutic areas
- CardiovascularRheumatologyImmunologyOncologyNeurology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
10 assets9 more assets in the full pipeline.
Beyond the preview
Go deeper on iLeadBMS.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iLeadBMS.